Aegle Therapeutics Corporation is the first extracellular vesicle (EV) company to be cleared by the FDA to enter clinical trials in humans. Headquartered in Miami, FL, the company is using allogeneic bone marrow mesenchymal stem cell (BM-MSC) derived extracellular vesicles to treat severe dermatological disorders, with a focus on burn treatments.
In May 2018, Aegle announced that the FDA cleared its first Investigational New Drug (IND) application to initiate a clinical trial in severe second degree burn patients. The company plans to launch a Phase 1/2a clinical trial of its lead product AGLE-102 in late 2018.
The open label dose escalation study will enroll patients at several sites in the U.S., evaluating the safety of extracellular vesicle therapy in burn patients. [Read more…]
CELLforCURE is a French pharmaceutical group that is authorized to do CAR-T manufacturing at its bioproduction site in Les Ulis (Essonne). CELLforCURE holds two Good Manufacturing Practice (GMP) certificates that allows it to manufacture experimental and commercial cell and gene therapies.
CryoHoldco has announced the acquisition of Criocord, a cord blood bank and cell therapy institute in Perù, for an undisclosed sum. CryoHoldco already owns the cord blood market leaders in Mexico and Colombia and now controls an important asset in Peru. A portfolio company of ACON investments, CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the largest cord blood banks worldwide. 
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has contracted with the Cell Manipulation Core Facility at Dana-Farber Cancer Institute to 
On June 25, 2018, Bio-Techne announced it is acquiring Exosome Diagnostics for $250 million in cash and up to $325 million for achieving certain milestones. As exosome therapeutics and diagnostics have multiplied in number, a number of investors have placed big bets on this rapidly growing marketplace.
